Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa : a cross-sectional study by Moodley, Jennifer R. et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
Human papillomavirus prevalence, viral load and pre-cancerous 
lesions of the cervix in women initiating highly active antiretroviral 
therapy in South Africa: a cross-sectional study
Jennifer R Moodley*1, Deborah Constant1, Margaret Hoffman1, 
Anna Salimo3, Bruce Allan2, Ed Rybicki2,3, Inga Hitzeroth3 and Anna-
Lise Williamson2,4
Address: 1School of Public Health and Family Medicine, Women's Health Research Unit, University of Cape Town, Cape Town, South Africa, 
2Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa, 3Department of Molecular and Cell 
Biology, University of Cape Town, Cape Town, South Africa and 4National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South 
Africa
Email: Jennifer R Moodley* - Jennifer.moodley@uct.ac.za; Deborah Constant - Deborah.Constant@uct.ac.za; 
Margaret Hoffman - Margaret.Hoffman@uct.ac.za; Anna Salimo - Anna.Salimo@uct.ac.za; Bruce Allan - Bruce.Allan@uct.ac.za; 
Ed Rybicki - Ed.Rybicki@uct.ac.za; Inga Hitzeroth - Inga.Hitzeroth@uct.ac.za; Anna-Lise Williamson - Anna-Lise.Williamson@uct.ac.za
* Corresponding author    
Abstract
Background: Cervical cancer and infection with human immunodeficiency virus (HIV) are both important public health
problems in South Africa (SA). The aim of this study was to determine the prevalence of cervical squamous intraepithelial
lesions (SILs), high-risk human papillomavirus (HR-HPV), HPV viral load and HPV genotypes in HIV positive women
initiating anti-retroviral (ARV) therapy.
Methods: A cross-sectional survey was conducted at an anti-retroviral (ARV) treatment clinic in Cape Town, SA in
2007. Cervical specimens were taken for cytological analysis and HPV testing. The Digene Hybrid Capture 2 (HC2) test
was used to detect HR-HPV. Relative light units (RLU) were used as a measure of HPV viral load. HPV types were
determined using the Roche Linear Array HPV Genotyping test. Crude associations with abnormal cytology were tested
and multiple logistic regression was used to determine independent risk factors for abnormal cytology.
Results: The median age of the 109 participants was 31 years, the median CD4 count was 125/mm3, 66.3% had an
abnormal Pap smear, the HR-HPV prevalence was 78.9% (Digene), the median HPV viral load was 181.1 RLU (HC2
positive samples only) and 78.4% had multiple genotypes. Among women with abnormal smears the most prevalent HR-
HPV types were HPV types 16, 58 and 51, all with a prevalence of 28.5%. On univariate analysis HR-HPV, multiple HPV
types and HPV viral load were significantly associated with the presence of low and high-grade SILs (LSIL/HSIL). The
multivariate logistic regression showed that HPV viral load was associated with an increased odds of LSIL/HSIL, odds
ratio of 10.7 (95% CI 2.0 – 57.7) for those that were HC2 positive and had a viral load of ≤ 181.1 RLU (the median HPV
viral load), and 33.8 (95% CI 6.4 – 178.9) for those that were HC2 positive with a HPV viral load > 181.1 RLU.
Conclusion: Women initiating ARVs have a high prevalence of abnormal Pap smears and HR-HPV. Our results
underscore the need for locally relevant, rigorous screening protocols for the increasing numbers of women accessing
ARV therapy so that the benefits of ARVs are not partially offset by an excess risk in cervical cancer.
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Cervical cancer and infection with human immunodefi-
ciency virus (HIV) are both important public health prob-
lems in South Africa (SA). Among South African women
cervical cancer is the second commonest cancer, with an
age standardized incidence rate of 30 per 100 000 per
year, and is the leading cause of cancer mortality [1]. SA is
confronted by one of the worst HIV epidemics in the
world and it is estimated that there are currently 5.4 mil-
lion people with HIV/AIDS in SA, with women more
severely affected than men [2]. Studies have shown that
women infected with HIV have a higher prevalence of
human papillomavirus (HPV) infection, are more likely
to develop persistent HPV infection, are more frequently
infected with multiple HPV types and are at a greater risk
of developing cervical squamous intraepithelial lesions
(SIL) and cervical cancer. These lesions are more aggres-
sive, persistent and more likely to recur following treat-
ment [3-11]. A recent study in South Africa has confirmed
that HIV positive women are at an increased risk of cervi-
cal SILs [12].
Highly active antiretroviral therapy (HAART) has been
shown to decrease HIV viral loads, increase CD4 cell
counts and decrease most opportunistic infections. Since
the introduction of HAART there has been a decline in cer-
tain malignancies in HIV infected individuals [13,14].
However studies on the impact of HAART on the natural
history of cervical squamous intraepithelial lesions (SILs)
have produced inconsistent results [15,16]. As anti-retro-
viral (ARV) therapy becomes increasingly available in the
public sector in South Africa, the life expectancy of HIV
positive women will increase. HPV-associated disease will
also become more clinically relevant and rigorous screen-
ing protocols are needed so that the benefits of ARVs are
not partially offset by an excess risk in cervical cancer.
These screening protocols need to be locally relevant. Few
studies have examined the prevalence of cervical dysplasia
in women initiating ARVs in South Africa [17]. The aim of
this study was to determine the prevalence of cervical SILs,
high-risk HPV (HR-HPV), HPV viral load and HPV geno-
types in HIV positive women initiating ARV therapy.
Methods
A cross sectional survey was conducted at a public sector
ARV treatment clinic in Cape Town, South Africa, between
January and May 2007. Women, eighteen years and older,
who were being considered for initiation of ARV therapy
were informed of the study by the clinic staff. Those indi-
cating interest were referred to the research nurse, who
explained the details of the study and obtained informed
consent. Women who had a hysterectomy, were menstru-
ating or pregnant at the time of the study were excluded.
The research nurse collected data on socio-demographic
status, sexual behavior, history of a sexually transmitted
infection (STI), obstetric and gynaecology history and risk
factors for cervical cancer using a structured question-
naire; conducted a pelvic examination; took a Pap smear
using a cytobrush and collected cervical samples for HPV
testing with Digene cervical samplers. The samples for
HPV testing were stored in Digene transport medium at -
80°C until required. CD4 count data were extracted from
clinical records. Pap smears were interpreted at the South
African National Health Laboratory Service and classified
according to the Bethesda classification system [18].
Women with high-grade squamous intraepithelial lesions
(HSIL) were referred to the regional colposcopy clinic and
those with other abnormalities asked to return for repeat
Pap smears according to the clinic protocol. Cervical sam-
ples were assayed for HPV infection using the Digene
Hybrid Capture 2 (HC2) assay which detects13 HR-HPV
genotypes. The HC2 results are given as a relative light
unit (RLU) ratio which is the ratio of light emitted by the
specimen to the light emitted from the mean RLU of trip-
licate positive control specimens containing 1 pg/ml of
HPV DNA (5000 copies of HPV genome). Specimen RLU
values were converted into a ratio to the cut-off value (1
pg/ml). Specimens with a ratio of < 1.00 were considered
negative, and those with a ratio of ≥ 1.00 were considered
positive. Low, but positive RLU values were not retested
and were considered positive for the purposes of the anal-
ysis. HPV types were determined using the Roche Linear
Array HPV Genotyping test, which identifies 37 different
HPV genotypes. The cyto-technician and laboratory tech-
nician were blinded to the clinical profile of the clients.
Data analysis was conducted using the statistical program
STATA 9.0 (STATA Corporation, College Station, Texas).
Descriptive statistics (medians and proportions) were
used to characterize the variables. Basic crude associations
with abnormal cytology were tested using Wilcoxon Rank
Sum tests for medians and Chi-square and Fischer's Exact
tests for proportions. Multivariate logistic regression was
carried out to determine independent risk factors for low-
grade squamous intra-epithelial lesions (LSILs) and high-
grade squamous intra-epithelial lesions (HSIL). To avoid
co-linearity in the model between HPV infection meas-
ured by the HC2 test and HPV viral load, we derived cate-
gories of HPV infection as follows: HPV HC2 negative as
the referent group and HPV HC2 positive in categories
according to the median viral load. Other variables
included in the model are known to be associated with
cervical abnormality and were: age, number of sexual
partners, age at first sexual intercourse and CD4 count.
Median values were used as cut-offs to categorize these
variables. Ethical approval was granted by the Research
Ethics Committee of the University of Cape Town.
Results
A total of 120 women were referred by clinic staff to par-
ticipate in the study. Nine women were excluded because
they were menstruating and two declined to participatePage 2 of 8
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included in the study. The socio-demographic and repro-
ductive characteristics for the overall study population
and according to cervical cytology results are presented in
Table 1. A total of 98/109 women had an adequate Pap
smear and of these 65 (66.3%) had an abnormal Pap
smear. Atypical squamous cells of undetermined signifi-
cance (ASCUS) was reported in 15 (15.3%), LSIL in 39
(40.0%), HSIL in 10 (10.2%) and atypical squamous
cells-cannot exclude HSIL (ASC-H) in 1 (1.0%) of
women. For analysis the cytology results were grouped as
normal/ASCUS versus LSIL/HSIL.
Overall the median age was 31 years (range 20 – 60 years).
The majority of women were unemployed (80.7%), just
under half (47.7%) were either married or in a stable rela-
tionship and most participants had attended high school
(median of 10 years of schooling). There were no signifi-
cant socio-demographic differences between women with
normal/ASCUS Pap smears and women with LSIL/HSIL
Pap smears.
The majority of the participants (55.0%) were currently
on contraception (data not shown). Of these, 40% were
using condoms only, 28% condoms and another contra-
ceptive method, 23% injectable contraception, 2% oral
contraception and 6% another method. There was no sig-
nificant difference in contraceptive use between women
with a normal/ASCUS Pap smear and those with a LSIL/
HSIl Pap smear. Most women reported having had an STI
(84.4%). Of these 27.1% gave a history of having an STI
in the preceding week. The median CD4 cell count was
125.0/mm3 (range 14.0 – 1047.0/mm3), with no signifi-
cant difference in the median CD4 count between women
with normal/ASCUS Pap smears and women with LSIL/
HSIL Pap smears.
Women with LSIL/HSIL Pap smears had a significantly
higher prevalence of HR-HPV compared to those with
normal/ASCUS Pap smears on both the Digene (95.9%
vs. 58.3% and Roche assays (100% vs. 77.1%), had a
higher median HPV viral load (444.1 vs. 60.3 RLU)
among those with HC2 positive samples and a higher
prevalence of multiple HPV types present (91.8% vs.
62.2%). Of the 109 participants: 85 tested positive on
both the Roche Linear Array and Digene HC2 tests, 12
were positive on the Roche but negative on the Digene
test, 11 were negative on both tests and 1 was negative on
the Roche test but positive on the Digene test. The preva-
lence of HR-HPV using the Digene test was 78.9% (95%
CI 69.8% – 85.9%) and using the Roche Linear Array HPV
Genotyping test the prevalence of HR-HPV was 89.0%
(95% CI 81.20 – 93.93).
The estimated median HPV viral load was 64.8 RLU for all
samples that had HC2 testing and 181.1 RLU for those that
samples that were HC2 positive based on the 1.0 pg/ml
clinical cut-off point. Table 2 provides information on the
median HC2 viral load and inter-quartile range by each cat-
egory of cervical abnormality. There was a significant trend
of increasing HPV viral load with increasing severity of
cytological abnormality both when restricting the analysis
to HC2 positives (p = 0.002) and when including all sam-
ples (p < 0.0001). Both analyses showed an overlap in the
range of viral loads for the cytology categories.
When stratified by CD4 count category, median HPV viral
loads were as follows: for those with CD4 < 100 (N = 38),
median HPV viral load = 23.5 RLU; CD4 ≥100 < 200 (N =
63), median HPV viral load = 97.3 RLU and CD4 ≥200 (N
= 8), HPV viral load = 8.9 RLU. The correlation between
log CD4 load and log HPV viral load was not significant
(correlation coefficient r = -0.005)
On Roche Liner Array testing a total of 35 HPV genotypes
were detected in the 109 women. The median number of
HPV types per woman was 3 (range 0 – 12), with multiple
genotypes (≥2 types) being detected in 69.7% of all partic-
ipants and in 78.4% of participants with a positive HC2
test. Figure 1 gives the prevalence of HPV types detected.
Overall HPV types 61 and 66 were most commonly
detected, with a prevalence of 23.9% and 18.5% respec-
tively. The prevalence of HPV 16 and 18 was 13.8% and
15.6% respectively and the prevalence of types 6 and 11
was 2.75% and 4.6%, respectively. Among women with
abnormal smears the most prevalent HR-HPV types were
HPV types 16, 58 and 51, all with a prevalence of 28.5%,
followed by HPV types 66 (24.6%), 18 (21.5%) and 45
(20.0%). Among the 10 women with HSIL the most com-
mon HR-HPV type was HPV 45 (prevalence 40%), fol-
lowed by HPV types 16, 35, 39, 58 and 51 all with a
prevalence of 30% and HPV types 18, 31, 33 and 66 all
with a prevalence of 20%.
Multivariate logistic regression was carried out to deter-
mine independent risk factors for HSIL/LSIL. The model
showed that HPV viral load was associated with an
increased odds of LSIL/HSIL. The odds of LSIL/HSIL was
10.7 (95% CI 2.0 – 57.7) for those that were HC2 positive
and had a viral load of ≤ 181.1 RLU (the median HPV viral
load), and for those that were HC2 positive with a HPV
viral load > 181.1 RLU the odds was 33.8 (95% CI 6.4 –
178.9). The odds ratio (OR) for LSIL/HSIL for the other
variables were as follows: age OR = 0.94 (95% CI 0.36 –
2.45), number of sexual partners OR = 0.88 (95% CI 0.31
– 2.47, age at first sexual intercourse OR = 0.47 (95% CI
0.16 – 1.32), and CD4 count OR = 1.11 (95% CI 0.42 –
2.96).
Discussion
Our study of women initiating ARV therapy recorded an
exceptionally high prevalence of cervical abnormalitiesPage 3 of 8
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Table 1: Socio-demographic and reproductive characteristics for the overall study population and according to cervical cytology 
results
Characteristic Overall
N = 109
Normal/
ASCUS
Pap smear
N = 48
LSIL/HSIL Pap smear
N = 49
P valuea
Data are N (%) except where otherwise specified
Median age in years
(range)
31 (20 – 61) 32 (20 – 57) 30 (20 – 61) 0.43
Employed 21 (19.3) 12 (25) 7 (14.3) 0.18
Ever smoked 21 (19.3) 5 (10.4) 16 (32.7) 0.03
Married or in stable relationship 52 (47.7) 22 (45.8) 23 (46.9) 1.00
Median years of school attendance (range) 10 (0 – 13) 10 (0 – 13) 9 (0 – 13) 0.42
Ever pregnant 89 (81.7) 40 (83.3) 39 (79.6) 0.64
Ever used injectable contraception 97 (89.0) 43 (89.6) 42 (85.7) 0.56
Ever used oral contraception 29 (26.6) 11 (22.9) 13 (26.5) 0.68
Ever used condoms 55 (50.5) 21 (43.8) 29 (59.2) 0.13
Median age of first intercourse (range) 17 (4 – 25) 17 (13 – 21) 16 (4 – 25) 0.12
Median number of sexual partners (range) 4 (1 – 13) 4 (1 – 10) 4 (1 – 13) 0.15
Ever had an STI 92 (84.4) 41 (85.4) 42 (85.7) 0.97
Past Pap smear 46 (42.2) 23 (47.9) 16 (32.7) 0.10
Median CD4 count
(range)
125 (14 – 1047) 125.5 (14 – 1047) 123 (32 – 313) 0.95
HR-HPV present
(Digene)
86 (78.9) 28 (58.3) 47 (95.9) < 0.001
HR-HPV present
(Roche)
97 (89.0) 37 (77.1) 49 (100) < 0.001
Median HPV viral load in RLU (range)
All samples
64.3 (0.12 – 2248.95) 3.19 (0.12–1373.77) 365.49 (0.21–2248.95) < 0.001
Median HPV viral load in RLU (range)
Only HC2 positives
181.06 (1.19–2248.95) 60.3 (1.19–1373.77) 444.07 (11.98–2248.95) 0.001
Prevalence of multiple HPV types
Only HC2 positives
76 (78.4) 23 (62.2) 45 (91.8) 0.001
a P values are from Wilcoxon Rank Sum tests for medians and chi-squared tests for proportions or Fisher's exact tests where numbers in the cells 
were < 5.
ASCUS, atypical squamous cells of undetermined significance; LSIL, low grade squamous intra-epithelial lesions; HSIL, high-grade squamous 
intraepithelial lesions; HPV, human papillomavirus; STI, sexually transmitted infection; HR-HPV, high-risk human papillomavirus; RLU, relative light 
units; HC2, Hybrid Capture 2
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conducted among HIV positive women in developed
countries [4,10,19-21] and is one of the highest recorded
in Africa [9,12,22,23]. Previous studies conducted among
HIV positive women in the Western Cape Province in
South Africa have recorded abnormal Pap smear preva-
lence of 50 to 55% [12,17]. These latter studies were con-
ducted in women with either an unknown CD4 status or
a higher median CD4 status than was recorded in our
study. The associations between low CD4 counts, HPV
and cervical dysplasia have been previously documented
[10,20]. Given the low CD4 counts in our study popula-
tion, severe immunosuppression is the most likely expla-
nation for the high prevalence of cervical abnormalities
and HPV detected. The only study to report a higher prev-
alence of cytological abnormalities than our study, was
that conducted by Parham et al among women attending
an HIV-care clinic at a tertiary centre in Zambia (abnormal
Pap smear prevalence of 94%) [22]. The latter study was
conducted among women with a median CD4 count of <
200 μ/L and of a similar age to our study population.
However in the Parham study cytological abnormalities
were detected by monolayer liquid cytology, which is
known to have a higher sensitivity than conventional
cytology, used in our study. The high prevalence of cervi-
cal abnormalities, in this sub-group of severely immuno-
compromised HIV positive women, has major health
planning and resource implications, particularly as ARVs
become increasingly more available in South Africa. The
results underscore the importance of developing screen-
ing and management guidelines for women initiating
ARVs that take into account the enormous disease burden
in the context of a constrained resource setting.
HR-HPV was present in 79% (Digene) of the women in
our study. This is amongst the highest HR-HPV prevalence
recorded in the literature [9,19,24] and is a cause for con-
cern. Previous studies have documented an increase in
HPV viral load with increasing severity of cervical lesions
[25-27]. In this study we assessed HPV viral load using the
HC2 test, which provides a semi-quantitative assessment
of viral load. HC2 as a measure of viral load can be mean-
ingful in some settings, however as this is a semi-quanti-
tative test results need to be interpreted with caution,
understood within the context of the setting and consider-
ation given to the presence of single or multiple-type HPV
infections. Some studies have shown that HC2 results can
be considered as reflective of HPV viral load [28] while
Table 2: HPV viral load and cervical cytology
Cervical cytology N Median HPV Viral load in RLUa
(interquartile range)
Normal 33 1.19 (0.19 – 14.30)
17 14.3 (3.28 – 190.06)
ASCUS 15 48.19 (0.59 – 218.51)
11 90.27 (33.59 – 232.08)
LSIL 39 308.33 (54.31 – 1259.64)
37 365.49 (82.06 – 1259.64)
HSIL 10 594.55 (177.5 – 1504.88)
10 594.55 (177.5 – 1504.88)
For HC2 all samples: Ptrend < 0.0001
For HC2 positives only: Ptrend = 0.002
aViral load in regular types represents viral load from all samples with HC2 testing and in italics from the HC2 positive samples only
HPV, human papillomavirus; HC2, Hybrid Capture 2; RLU, relative light units; ASCUS, atypical squamous cells of undetermined significance; LSIL, 
low grade squamous intra-epithelial lesions; HSIL, high-grade squamous intraepithelial lesions
Prevalence of HPV types detected in 109 women initiating HAARTFigur  1
Prevalence of HPV types detected in 109 women ini-
tiating HAART. aTypes 26, 53 and 66 are usually classified 
as probably oncogenic, but in this analysis were grouped with 
oncogenic types to simplify interpretation.
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test will give meaningful results in cervical specimens
from HIV positive women who are more likely to be
infected with multiple HPV types compared to HIV nega-
tive women [30]. HIV positive women are at higher risk of
cervical abnormalities but it is not known how many HPV
types, in HIV positive women infected with multiple HPV
types, contribute to cervical disease [26]. In this paper we
investigated whether an increased HPV viral load, as
measured by HC2, reflects increased risk of cervical dis-
ease if the result is a combination of many HPV types
instead of only one type and found an association
between HPV viral load and severity of cervical cytological
abnormality. We speculate that HPV viral load might be
clinically useful in predicting cervical dysplasia in HIV
positive women if a higher cut-off point is used. However
any change in the cut-off point will result in changes in
test sensitivity as well and longitudinal studies are needed
to test this hypothesis. It has been previously reported that
cervical intraepithelial neoplasia with high viral loads are
more likely to persist than those with a low level of HR-
HPV [31]. It is critical that we determine the natural his-
tory of HR-HPV among women initiating ARVs as it is
known that women with persistent HR-HPV are at an
increased risk of developing cervical abnormalities.
Clifford et al have shown that there is considerable varia-
tion in regional HPV type distribution [30]. In our study
the most common prevalent HPV types among all women
were types 61 (23.9%), 66 (18.5%), 58 (17.4%), 18
(15.6%), 45 (15.6%) and 70 (15.6%); and the most com-
mon types among women with cervical abnormalities
were types16 (28.5%), 58(28.5%), 53(28.5%),
51(28.5%), 66 (24.6%), 18 (21.5%) and 45 (20.0%). As
has been shown in other studies, HPV 16 did not predom-
inate over other types to the same extent as is usually seen
in HIV negative women [32-36]. The majority of our par-
ticipants had multiple HPV genotypes. Although types 16
and 18 were among the commonest HPV types seen in
women with cervical abnormalities, we found a relatively
high prevalence of HPV types not covered by the HPV vac-
cine. This has been documented by others and has impor-
tant implications for the potential impact of HPV vaccines
currently available.
The small sample size limited our power to assess the
association between LSIL/HSIL and potential predictors. A
strong association between HIV viral load and cervical
abnormalities has been demonstrated in other studies
[10,20,37]. We were unable to collect data on HIV viral
load. Another limitation was that cytological abnormali-
ties could not be histologically confirmed in all women.
However there is no reason to believe that the cytologists
would have over-diagnosed cytological abnormalities
because of the known association between HIV and cervi-
cal pre-cancerous lesions, as the cytologists were unaware
of the participant's HIV status. It is possible that the true
prevalence of cervical abnormalities might in fact be
higher than we recorded, as the sensitivity of Pap smears
has been shown to be as low as 20% [38,39].
Conclusion
In summary, women initiating HAART in SA have an
extremely high prevalence of abnormal Pap smears and
HR-HPV and this has major health planning and resource
implications. It is critical that we develop locally relevant,
rigorous screening protocols for the increasing numbers
of women accessing ARV therapy. Further studies are
needed to explore the predictive role of HPV viral load
using higher cut-off points in HIV-positive women.
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